London, UK – 4th December 2024. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage speciality pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, will support the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders (SCWD) from 6 – 8 December 2024 in Washington DC. 

Actimed will support the symposium entitled “Innovations in cancer cachexia” on 6 Dec at 17.45 which will include the following presentations:
Cancer cachexia: New pharmacological approaches Richard Skipworth, Honorary Professor, University of Edinburgh, NRS Clinician, UK

Are patient reported outcomes meaningful endpoints in cachexia trials?
Stacie Hudgens, Chief Executive Officer & Principal Scientific Advisor, Clinical Outcomes Solutions, USA

Innovations in cancer cachexia: S-pindolol a new therapeutic approach 
Andrew Coats, Scientific Director and CEO, Heart Research Institute, Australia

The session will be moderated by Stefan Anker and Andrew Coats.

Full conference details are available on the SCWD website, here. 

About Actimed Therapeutics  

Actimed Therapeutics is a clinical stage speciality pharmaceutical company focused on bringing innovation to the treatment of cachexia and other muscle wasting disorders, to transform the care of an underserved and vulnerable patient population. 

Cachexia is a wasting disease that is associated with cancer and other serious chronic illnesses and with significant morbidity and mortality. A significant number of cancer patients suffer from cachexia, and it is estimated that cachexia is responsible for up to 20% of all cancer deaths. Despite its prevalence and devastating clinical effects, there is no globally approved drug for the treatment or prevention of cancer-related cachexia.  

Actimed’s lead product, S-pindolol benzoate (ACM-001.1), targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients. Actimed is currently preparing for further clinical studies in cancer cachexia having received an Investigational New Drug (IND) approval from FDA for this programme in August 2023. 

Actimed also owns the global rights to its second asset, S-oxprenolol, which is being developed by the Company for the muscle wasting seen in amyotrophic lateral sclerosis (ALS) where loss of body mass and muscle wasting may impact survival. Actimed has licensed the global rights to develop and commercialise S-oxprenolol for cancer cachexia and any other indications outside of ALS to US company Faraday Pharmaceuticals.

FOR MORE INFORMATION

Actimed Therapeutics

MEDiSTRAVA 
Frazer Hall, Erica Hollingsworth
Tel: +44 (0)203 928 6900
Email: actimed@medistrava.com